Federal Circuit denies Novartis’ bid to halt generics

29-09-2022

Staff Writer

Federal Circuit denies Novartis’ bid to halt generics

Taljat David / Shutterstock.com

Bid to stay invalidity decision pending a SCOTUS appeal fails | Patent covers a multiple sclerosis drug | Company could take $300m hit if generics are launched.


Novartis, Federal Circuit, patent, patent infringement, HEC Pharm, Gilenya, generics, multiple sclerosis, SCOTUS

LSIPR